SPH6162

**SPH6162** is a small molecule Wee1 inhibitor developed by Shanghai Pharmaceuticals for oncology indications. Wee1 is a nuclear kinase of the Ser/Thr family that regulates the G2 cell cycle checkpoint by inhibiting Cdk1, preventing mitotic entry in response to DNA damage; inhibition of Wee1 impairs tumor cell DNA repair, sensitizing them to radiotherapy, chemotherapy, or synthetic lethality in mutated tumors. It demonstrates superior target kinase selectivity, higher potency, and better tumor tissue distribution compared to other Wee1 inhibitors in development, with overexpression of Wee1 observed in solid tumors such as hepatocellular carcinoma, colon cancer, glioblastoma, non-small cell lung cancer, neuroblastoma, and gastric cancer.[1][4][7][13]